Exploring the Latest Developments in Natural Killer(NK)Cell-Based Therapies for Diffuse Intrinsic Pontine Glioma(DIPG)OA

Diffuse intrinsic pontine glioma(DIPG)is a pediatric brainstem tumor with a very poor prognosis,characterized by immunosuppressive tumor microenvironment(TME)that limits immune infiltration,including a significant reduction in circulating natural killer(NK)cells.This drop in NK cell levels and activity may promote tumor growth and immune evasion,making NK cells a promising target for immunotherapy.NK cells can attack and eliminate DIPG tumor cells,including glioma stem cells,while counteracting certain immune evasion strategies.Although theDIPGmicroenvironment and blood-brain barrier present challenges,NKcell-based therapies have shown encouraging tumor control and survival benefits in animal models with promising safety results.Current clinical trials for DIPG mostly focus on chimeric antigen receptor(CAR)-T cells targeting disialoganglioside(GD2)and cluster of differentiation 276(CD276 or B7-H3)antigens with early signs of success,while NK cell therapies,such as CAR-NK cells,are still in preclinical or early stages,requiring further development.The tumor’s immunosuppressive nature poses challenges that may need combination strategies or immune priming.Despite these obstacles,NK cell-based immunotherapy is an exciting and growing field.Upcoming clinical trials emphasize the potential for NK cell therapies to play a critical role in treating this aggressive pediatric brain cancer.